Q-omics provides the consensus-scored RPL17P15 profile across patient tissues and cancer cell-line models. RPL17P15 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL17P15 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL17P15 RNA expression shows 13,835 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where RPL17P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P15 survival associations across molecular data types. RPL17P15 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P15 RNA expression–survival associations across cancer types. High RPL17P15 expression shows unfavorable associations in ACC, THCA, UVM and LUSC, but favorable associations in BLCA and OV. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL17P15 RNA expression.
This table summarizes RPL17P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P15 shows lower tumor expression in KIRC, KIRP, THCA and KICH and higher tumor expression in HNSC and CHOL. The KIRC box plot shows higher RPL17P15 RNA expression in normal versus tumor tissue (log2 FC = −0.554, t-test p < 0.001).
This table shows molecular features associated with RPL17P15 in patient tissues and cancer cell lines. In patient samples, RPL17P15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
